WCN25-799 EFFICACY AND SAFETY OF IPTACOPAN IN PATIENTS WITH IgA NEPHROPATHY (IgAN): INTERIM ANALYSIS (IA) OF THE PHASE 3 APPLAUSE-IgAN STUDY

• Dmitrij Kollins,
• Olympia Papachristofi,
• Thomas Hach,
• Severina Jacinto-Sanders,
• Tobias Merkel,
• Ronny Renfurm,
• Vlado Perkovic

Affiliations

Dmitrij Kollins

Cardio-Renal-Metabolic GDD, Novartis Pharma AG, Basel, Switzerland

Olympia Papachristofi

Cardio-Renal-Metabolic GDD, Novartis Pharma AG, Basel, Switzerland

Thomas Hach

Cardio-Renal-Metabolic GDD, Novartis Pharma AG, Basel, Switzerland

Severina Jacinto-Sanders

Cardio-Renal-Metabolic GDD, Novartis Pharma AG, Basel, Switzerland

Tobias Merkel

Cardio-Renal-Metabolic GDD, Novartis Pharma AG, Basel, Switzerland

Ronny Renfurm

Cardio-Renal-Metabolic GDD, Novartis Pharma AG, Basel, Switzerland

Vlado Perkovic

Renal and Metabolic Division, University of New South Wales, Sydney, Australia